Keyword Search
 
2017
DateTitle 
11/09/17Aileron Therapeutics Reports Third Quarter 2017 Financial Results
Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS Two abstracts selected for oral presentations at American Society of Hematology Annual Meeting, highlighting potential of p53-reactivating ALRN-6924 in the treatment of PTCL and AML CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today rep... 
Printer Friendly Version
11/01/17Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
Two abstracts selected for oral presentations, highlighting the potential of p53-reactivating ALRN-6924 in the treatment of PTCL and AML CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced that two abstracts on the Company’s lead product candidate, ALRN-6924, have been accepted for oral presentation at the 59th American Society ... 
Printer Friendly Version
09/19/17Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on September 15, 2017, as part of Russell’s quarterly additions of companies with recent initial public offerings. The Russell 2000 Index measures the perfo... 
Printer Friendly Version
08/24/17Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
Collaboration with Albert Einstein College of Medicine studies effect of targeting MDMX and MDM2 with ALRN-6924 in AML CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that preclinical data from its collaboration with Albert Einstein College of Medicine on ALRN-6924 in acute myeloid leukemia will be reviewed in an oral presentation at th... 
Printer Friendly Version
08/10/17Aileron Therapeutics Reports Second Quarter 2017 Financial Results
Initial clinical data showing anti-tumor activity with ALRN-6924 presented at ASCO 2017  -Presentation selected for Best of ASCO Meetings Ongoing enrollment of clinical trials in PTCL and AML/MDS Initial public offering raised $50 million in net proceeds ALRN-6924 granted Orphan Drug designation in AML CAMBRIDGE, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other d... 
Printer Friendly Version
08/03/17Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III, President and CEO, will present at the Canaccord Genuity 37th Annual Growth Conference. Conference Details: Event:   Canaccord Genuity 37th Annual Growth Conference Date:   Thursday, August 10, 2017 Time... 
Printer Friendly Version
06/28/17Aileron Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Aileron. In addition, Aileron has granted the und... 
Printer Friendly Version
06/15/17Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer
CAMBRIDGE, MA—June 15, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the appointment of Donald Dougherty as senior vice president and chief financial officer, effective June 8th.Mr. Dougherty joins Aileron with more than 30 years of financial leadership experience. He founded Compound Capital Growth Investments (CCGrowth), LLC, a Boston investment firm focused ... 
Printer Friendly Version
06/03/17Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924
First clinical data reported on a dual inhibitor of MDMX and MDM2, key suppressors of P53 functionData reviewed in oral presentation at 2017 ASCO Annual MeetingCHICAGO, IL—June 3, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides, today announced safety and clinical activity data, including complete responses, partial responses and evidence of stable disease, from its Phase 1, multi-center trial with ALRN-6924 i... 
Printer Friendly Version
05/18/17Aileron Therapeutics Announces Oral Presentation at ASCO on ALRN-6924 Targeting p53
Abstract also selected for inclusion in the Best of ASCO® ProgramP53 stapled peptide product candidate ALRN-6924 granted orphan drug designation from FDA for treatment of acute myeloid leukemiaCAMBRIDGE, MA—May 18, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, today announced that the Company's abstract for ALRN-6924, its lead stapled peptide product candidate targeting p53, was selected for an oral presenta... 
Printer Friendly Version